Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM. Clin J Am Soc Nephrol. 2018 Jan 16. pii: CJN.05280517. doi: 10.2215/CJN.05280517. [Epub ahead of print] PMID: 29339356

High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136. [Epub ahead of […]

Cardiovascular Outcome Trials in Type 2 Diabetes: Lessons Learned and Future Outlook Total Cardiovascular Events Analysis of the EXAMINE Trial of Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome High Sensitivity C-Reactive Protein, Low-Density Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Acute Coronary Syndrome From the EXAMINE Trial Visit-to-Visit […]

Cardiovascular Effects of Incretin-Based Therapies. White WB, Baker WL. Annu Rev Med. 2016;67:245-60. doi: 10.1146/annurev-med-050214-013431. Review. PMID: 26768240 Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen […]

People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist just published in the British medical journal, The Lancet.